tirzepatide informacion en español Qué es la tirzepatida, el nuevo fármaco para tratar la diabetes tipo 2 y la obesidad aprobado por el ISP Chile Tirzepatida: usos, efectos secundarios, dosis

For most GLP-1 trials, HR is included as a secondary safety endpoint, and the results have been inconsistent

Key secondary endpoints included: 1) decrease of at least 1 fibrosis stage without worsening of MASH (i.e., no increase in NAFLD activity score)

Inclusion Criteria Exclusion Criteria Timeline for a Trial Participant Screening Participants are screened for eligibility to participate in the trial Treatment Participants receive weekly subcutaneous injections of either CagriSema or Tirzepatide, with a dose escalation period followed by maintenance dosing Follow-up Participants are monitored for safety and effectiveness after treatment What Are the Treatments Tested in This Trial

Weight Loss works by mimicking a hormone that regulates appetite and blood sugar